Skip to main content
Terug
Watch Compare

Opus Genetics, Inc.

Datakwaliteit: 100%
IRD
Nasdaq Manufacturing Chemicals
€ 5,36
▼ € 0,14 (-2,55%)
Marktkapitalisatie: 389,69 M
Prijs
€ 5,46
Marktkapitalisatie
389,69 M
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—

Quick Summary

Belangrijkste Punten

Revenue grew 121,57% annually over 5 years — strong growth
Debt/Equity of 0,18 — conservative balance sheet
Negative free cash flow of -35,25 M
Revenue growth is decelerating — 1Y growth trails 5Y average by 92,42%

Groei

Revenue Growth (5Y)
121,57%
Boven sectorgemiddelde (1,82%)
Revenue (1Y)29,15%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-423,13%
Onder sectorgemiddelde (-53,53%)
ROIC-239,09%
Net Margin-349,33%
Op. Margin-271,90%

Veiligheid

Debt / Equity
0,18
Onder sectorgemiddelde (0,31)
Current Ratio1,23
Interest Coverage-299,22

Waardering

PE (TTM)
-7,86
Onder sectorgemiddelde (-1,48)
P/B Ratio65,31
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1366 peers)
Metriek Aandeel Sector Mediaan
P/E -7,9 -1,5
P/B 65,3 1,6
ROE % -423,1 -53,5
Net Margin % -349,3 -41,5
Rev Growth 5Y % 121,6 1,8
D/E 0,2 0,3

Koersdoel Analisten

14 analisten
Buy
Huidig
€ 5,36
+85.2%
Koersdoel
€ 9,93
€ 8,00
€ 9,50
€ 15,00
Vooruitzicht
Forward K/W -9,43
Forward WPA -€ 0,57
Omzet Sch. 17,26 M

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2027 -€ 0,57
-€ 0,74 – -€ 0,28
 17,26 M 7
FY2026 -€ 0,57
-€ 0,72 – -€ 0,35
 16,18 M 7

Winstverassingen

Laatste 4 kwartalen
Kwartaal Geschat WPA Werkelijk WPA Verrassing
Q42025 -€ 0,10 -€ 0,21 -110,0%
Q32025 -€ 0,13 -€ 0,25 -92,3%
Q22025 -€ 0,26 -€ 0,12 +53,9%
Q12025 -€ 0,21 -€ 0,24 -17,1%

ETFs Holding This Stock

BOSVX BOSVX
0,00% weight
BSVO logo BSVO EA Bridgeway Omni Small-Cap Value ETF
0,00% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) 29,15% Revenue Growth (3Y) -13,67%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 121,57% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 14,20 M Net Income (TTM) -49,59 M
ROE -423,13% ROA -132,62%
Gross Margin N/A Operating Margin -271,90%
Net Margin -349,33% Free Cash Flow (TTM) -35,25 M
ROIC -239,09% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,18 Current Ratio 1,23
Interest Coverage -299,22 Asset Turnover 0,38
Working Capital 6,82 M Tangible Book Value 5,97 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -7,86 Forward P/E N/A
P/B Ratio 65,31 P/S Ratio 27,45
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -9,05%
Market Cap 389,69 M Enterprise Value 359,94 M
Per Share
EPS (Diluted TTM) -0,80 Revenue / Share 0,20
FCF / Share -0,49 OCF / Share -0,49
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 71,09%
SBC-Adj. FCF -38,65 M Growth Momentum -92,42

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 14,20 M 10,99 M 19,05 M 39,85 M 589.000,0
Net Income -49,59 M -57,53 M -9,99 M 17,89 M -56,69 M
EPS (Diluted) -0,80 -2,15 -0,46 0,87 -3,82
Gross Profit — — — — —
Operating Income -38,60 M -62,07 M -10,56 M 18,23 M -22,71 M
EBITDA — — — — —
R&D Expenses — — — — —
SG&A Expenses — — — — —
D&A — — — — —
Interest Expense 129.000,0 — 0,0 9.000,0 2.000,0
Income Tax 0,0 0,0 12.000,0 315.000,0 0,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 50,24 M 36,86 M 53,95 M 48,99 M 26,08 M
Total Liabilities 34,90 M 11,30 M 4,04 M 2,75 M 3,86 M
Shareholders' Equity 15,35 M 6,72 M 49,91 M 46,24 M 22,22 M
Total Debt 1,13 M — 600.000,0 0,0 538.000,0
Cash & Equivalents 45,09 M 30,32 M 50,50 M 42,63 M —
Current Assets 50,04 M 36,61 M 53,95 M 48,99 M 26,07 M
Current Liabilities 7,78 M 11,30 M 4,04 M 2,75 M 3,86 M